Wealthfront Advisers’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Wealthfront Advisers’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.63M	Buy	16,601 +460	+3%	+$62.2K	0.01%	565
2026 Q1	$2.06M	Buy	16,141 +1,990	+14%	+$248K	﹤0.01%	594
2025 Q4	$1.73M	Buy	14,151 +1,969	+16%	+$226K	﹤0.01%	617
2025 Q3	$1.22M	Buy	12,182 +652	+6%	+$58.7K	﹤0.01%	665
2025 Q2	$956K	Buy	11,530 +1,479	+15%	+$118K	﹤0.01%	687
2025 Q1	$815K	Sell	10,051 -1,115	-10%	-$99.7K	﹤0.01%	700
2024 Q4	$1.01M	Sell	11,166 -1,924	-15%	-$186K	﹤0.01%	666
2024 Q3	$1.29M	Sell	13,090 -39	-0.3%	-$3.83K	﹤0.01%	600
2024 Q2	$1.22M	Sell	13,129 -491	-4%	-$44K	﹤0.01%	589
2024 Q1	$1.29M	Buy	13,620 +3,526	+35%	+$327K	﹤0.01%	565
2023 Q4	$901K	Buy	10,094 +832	+9%	+$61.8K	﹤0.01%	610
2023 Q3	$676K	Buy	9,262 +1,733	+23%	+$138K	﹤0.01%	631
2023 Q2	$626K	Sell	7,529 -951	-11%	-$79.5K	﹤0.01%	643
2023 Q1	$646K	Buy	8,480 +354	+4%	+$29.4K	﹤0.01%	613
2022 Q4	$674K	Sell	8,126 -40	-0.5%	-$3.24K	﹤0.01%	577
2022 Q3	$648K	Buy	8,166 +734	+10%	+$61.9K	﹤0.01%	550
2022 Q2	$552K	Buy	7,432 +2,382	+47%	+$179K	﹤0.01%	574
2022 Q1	$454K	Buy	5,050 +2,409	+91%	+$222K	﹤0.01%	645
2021 Q4	$295K	Buy	+2,641	New	+$319K	﹤0.01%	685

Other funds holding XBI

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $72.7B AUM 39.36% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

MSR

Main Street Research Lakeville, Connecticut $2.12B AUM 67.44% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wealthfront Advisers's XBI Position: Q2 2026 in Review

Wealthfront Advisers increased its State Street SPDR S&P Biotech ETF (XBI) stake by 2.8% in Q2 2026, buying an estimated $62.2K and bringing the position to 16,601 shares worth $2.63M. The position accounts for 0.01% of the portfolio, ranked #565.

Wealthfront Advisers first reported a position in XBI in Q4 2021 and has held it in 19 quarters since. 701 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Wealthfront Advisers held 16,601 shares of State Street SPDR S&P Biotech ETF worth $2.63M as of Q2 2026.
Wealthfront Advisers bought 460 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $62.2K.
State Street SPDR S&P Biotech ETF made up 0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #565 holding.
Wealthfront Advisers first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and has held it in 19 quarters since.
701 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.